SCHEMBL5548145

SCHEMBL5548145

[O]C1Oc2ccccc2C1=O

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RET P07949 1/20 0.46
KDR P35968 1/20 0.46
MEN1 O00255 2/20 0.44
POLB P06746 2/20 0.44
KMT2A Q03164 2/20 0.44
CYP19A1 P11511 5/20 0.44
MAOB P27338 3/20 0.44
ADORA3 P0DMS8 3/20 0.44
AR P10275 2/20 0.44
KDM4E B2RXH2 1/20 0.44
HSD17B10 Q99714 1/20 0.44
STK17B O94768 1/20 0.44
PARP1 P09874 1/20 0.41
S100A4 P26447 1/20 0.39
PKM P14618 1/20 0.39
TSHR P16473 1/20 0.39
HSD11B1 P28845 1/20 0.39
AKR1C3 P42330 1/20 0.39
ALOX15 P16050 1/20 0.39
TDP1 Q9NUW8 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL69727 0.76 RET (0.53) RETKDRMEN1POLBKMT2A
SCHEMBL69430 0.76 PARP1 (0.48) RETKDRMEN1POLBKMT2A
SCHEMBL4775874 0.76 RET (0.45) RETKDRMEN1POLBKMT2A
SCHEMBL1429502 0.76 STK17B (0.46) RETKDRMEN1POLBKMT2A
SCHEMBL28875665 0.74 MEN1 (0.52) RETKDRMEN1POLBKMT2A
SCHEMBL29441433 0.74 MEN1 (0.52) RETKDRMEN1POLBKMT2A
SCHEMBL2838579 0.72 RET (0.58) RETKDRMEN1POLBKMT2A
SCHEMBL10513412 0.72 STK17B (0.51) RETKDRMEN1POLBKMT2A
SCHEMBL92288 0.72 ESR1 (0.45) RETKDRMEN1POLBKMT2A
SCHEMBL9434848 0.72 ESR1 (0.45) RETKDRMEN1POLBKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2570418-A2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles compound OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2013-03-20 EP disclosed
EP-1555267-B1 2,3-DIHYDRO-6-NITROIMIDAZO[2,1-b]OXAZOLES OTSUKA PHARMA CO LTD (JP) 2013-01-16 EP disclosed
US-7262212-B2 2,3-dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2007-08-28 US disclosed
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2006-05-04 US disclosed
EP-1555267-A1 2,3-DIHYDRO-6-NITROIMIDAZO 2,1-b OXAZOLES OTSUKA PHARMACEUTICAL CO., LTD. (JP) 2005-07-20 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060094767-A1 2,3-Dihydro-6-nitroimidazo[2,1-b]oxazoles NR2C2, NR4A3, NR4A2 RET 957/4885KDR 3886/4885MEN1 3295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.